Last 47 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.91 | — | — | — | — | — | — | — | — | — | 0.73 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.85 | 3.79 | 4.68 | 3.35 | 4.12 | 2.07 | 3.08 | 0.74 | 0.42 | 0.76 | 32.50 | 1.01 | 1.23 | 1.59 | 4.18 | 3.40 | 4.11 | 2.33 | 4.15 | 4.18 | 3.85 |
| — | +83.0% | +52.2% | +355.8% | +873.1% | +170.8% | -90.5% | -27.5% | -65.5% | -51.8% | +677.6% | -70.2% | -70.2% | -32.0% | +0.8% | -18.5% | +6.9% | -21.7% | +29.5% | +21.0% | +8.9% | |
| P/B Ratio | 1.52 | 3.56 | 2.93 | 2.80 | 2.17 | 0.71 | — | — | — | — | — | — | — | — | — | — | — | — | 79.39 | 12.55 | 9.71 |
| — | +402.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +852.5% | +131.3% | +54.8% | |
| P/FCF | — | — | — | — | — | — | — | 1.39 | — | 0.83 | — | — | — | — | — | — | — | — | — | — | 23.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +166.2% | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.9% | 70.4% | 61.9% | 61.2% | 59.5% | 57.0% | 51.3% | 37.5% | 70.7% | 54.5% | 37.7% | 7.6% | 56.1% | 57.7% | 48.0% | 68.7% | 22.4% | 81.3% | 84.4% | 83.5% | 74.2% |
| — | +23.5% | +20.5% | +63.5% | -15.8% | +4.5% | +36.3% | +392.9% | +25.9% | -5.5% | -21.5% | -88.9% | +150.3% | -29.0% | -43.2% | -17.7% | -69.8% | +0.4% | -7.2% | -6.6% | -19.4% | |
| Operating Margin | -425.7% | -226.0% | -293.7% | -359.9% | -365.0% | -443.6% | -597.9% | -78.0% | -9.0% | -31.6% | -2937.0% | -75.3% | -42.9% | -58.8% | -208.9% | -113.5% | -177.1% | -73.2% | -134.6% | -53.9% | -39.7% |
| — | +49.1% | +50.9% | -361.3% | -3944.4% | -1305.4% | +79.6% | -3.6% | +79.0% | +46.4% | -1306.2% | +33.7% | +75.8% | +19.6% | -55.1% | -110.7% | -345.7% | -165.4% | +33.2% | -462.3% | -233.8% | |
| Net Margin | -403.8% | -144.2% | -308.2% | -292.4% | -303.4% | -403.1% | -744.4% | -93.6% | -15.2% | -19.9% | 4457.3% | -87.0% | -53.2% | -73.0% | -233.5% | -129.8% | -190.8% | -83.4% | -159.8% | -62.3% | -46.7% |
| — | +64.2% | +58.6% | -212.3% | -1897.4% | -1927.2% | -116.7% | -7.6% | +71.4% | +72.8% | +2009.1% | +33.0% | +72.1% | +12.4% | -46.1% | -108.3% | -308.5% | -144.4% | +23.3% | -808.8% | -289.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -279.1% | -29.6% | -54.3% | -50.1% | -33.8% | -34.5% | — | — | — | — | — | — | — | — | — | — | — | — | -174.2% | -40.0% | -26.9% |
| — | +14.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -105.9% | -1206.4% | -325.5% | |
| ROA | -48.2% | -9.0% | -14.5% | -9.6% | -7.3% | -10.2% | -13.8% | -10.6% | -1.8% | -1.8% | 14.8% | -13.1% | -7.5% | -9.8% | -17.1% | -11.4% | -15.8% | -8.8% | -15.1% | -6.4% | -5.2% |
| — | +11.5% | -4.8% | +9.5% | -303.0% | -467.7% | -193.5% | +19.0% | +75.8% | +81.7% | +186.1% | -15.0% | +52.4% | -11.7% | -13.6% | -77.3% | -203.7% | -110.9% | +33.0% | -645.4% | -245.3% | |
| ROIC | -1103.8% | -145.3% | -179.4% | -183.1% | — | — | -426.7% | -65.9% | -6.9% | -15.8% | -31.4% | -23.0% | -9.7% | -10.4% | -18.6% | -20.5% | -52.4% | -26.3% | -56.0% | -20.6% | -11.3% |
| — | — | +58.0% | -177.8% | — | — | -1259.9% | -186.3% | +29.0% | -52.0% | -68.7% | -12.2% | +81.5% | +60.5% | +66.8% | +0.1% | -361.5% | -284.9% | +1.3% | -545.6% | -274.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.62 | 0.69 | 0.66 | 0.46 | 0.34 | — | — | — | — | — | — | — | — | — | — | — | — | 34.25 | 4.29 | 3.20 |
| — | +81.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +947.4% | +188.8% | +97.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.46 | 1.77 | 1.56 | 1.46 | 1.23 | 1.43 | 1.22 | 1.21 | 1.25 | 1.21 | 1.17 | 1.43 | 1.85 | 2.28 | 2.56 | 2.75 | 2.62 | 3.17 | 3.33 | 3.64 | 2.10 |
| — | +23.5% | +28.0% | +20.7% | -1.2% | +19.0% | +4.3% | -15.8% | -32.7% | -47.0% | -54.5% | -47.8% | -29.1% | -28.3% | -23.2% | -24.6% | +24.5% | +38.1% | +39.1% | -30.9% | -61.4% | |
| Quick Ratio | 1.43 | 1.70 | 1.52 | 1.43 | 1.23 | 1.42 | 1.20 | 0.96 | 1.09 | 1.07 | 1.05 | 1.24 | 1.58 | 1.90 | 2.16 | 2.47 | 2.45 | 2.95 | 3.09 | 3.42 | 1.98 |
| — | +19.7% | +26.5% | +49.5% | +12.9% | +32.3% | +14.5% | -22.9% | -31.0% | -43.6% | -51.4% | -49.6% | -35.8% | -35.7% | -30.2% | -27.7% | +23.8% | +36.4% | +40.8% | -31.2% | -61.7% | |
| Interest Coverage | -19.34 | -13.36 | -15.90 | -19.61 | -18.15 | -18.70 | -21.05 | -8.48 | -1.01 | -1.42 | -5.84 | -6.50 | -2.90 | -3.31 | -6.80 | -5.27 | -10.49 | -6.62 | -9.71 | -6.89 | -5.68 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CHRS stock.
Coherus Oncology, Inc.'s current P/E is -0.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Coherus Oncology, Inc.'s current operating margin is -425.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Coherus Oncology, Inc.'s business trajectory between earnings reports.